UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 111

Sortiert nach

Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner

Cell stem cell, 2014-01, Vol.14 (1), p.68-80

2014

Link zum Volltext

Verfügbarkeit prüfen

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Cell chemical biology, 2020-01, Vol.27 (1), p.41-46.e17

2020

Link zum Volltext

Verfügbarkeit prüfen

Modeling initiation of Ewing sarcoma in human neural crest cells

PloS one, 2011-04, Vol.6 (4), p.e19305-e19305

2011

Link zum Volltext

Verfügbarkeit prüfen

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma

Clinical cancer research, 2020-01, Vol.26 (1), p.46-53

2020

Link zum Volltext

Verfügbarkeit prüfen

Outcome-Driven Cluster Analysis with Application to Microarray Data

PloS one, 2015-11, Vol.10 (11), p.e0141874-e0141874

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5748-5754

2008

Link zum Volltext

Verfügbarkeit prüfen

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

Journal of medicinal chemistry, 2021-12, Vol.64 (23), p.17146-17183

2021

Link zum Volltext

Verfügbarkeit prüfen

B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

The American journal of surgical pathology, 2010-03, Vol.34 (3), p.327-340

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

The oncologist (Dayton, Ohio), 2017-03, Vol.22 (3), p.264-271

2017

Link zum Volltext

Verfügbarkeit prüfen

Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase

Bioorganic & medicinal chemistry letters, 2021-05, Vol.39, p.127904-127904, Article 127904

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Journal of translational medicine, 2017-06, Vol.15 (1), p.146-9, Article 146

2017

Link zum Volltext

Verfügbarkeit prüfen

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

Neuro-oncology (Charlottesville, Va.), 2015-05, Vol.17 (5), p.697-707

2015

Link zum Volltext

Verfügbarkeit prüfen

PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer

Cancer research (Chicago, Ill.), 2017-09, Vol.77 (17), p.4613-4625

2017

Link zum Volltext

Verfügbarkeit prüfen

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma

Clinical cancer research, 2019-06, Vol.25 (11), p.3239-3246

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

PloS one, 2015-10, Vol.10 (10), p.e0139679

2015

Link zum Volltext

Verfügbarkeit prüfen

Ewing Tumors That Do Not Overexpress BMI-1 Are a Distinct Molecular Subclass with Variant Biology: A Report from the Children's Oncology Group

Clinical cancer research, 2011, Vol.17 (1), p.56-66

2011

Link zum Volltext

Verfügbarkeit prüfen

Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types

Blood, 2021-11, Vol.138 (Supplement 1), p.2274-2274

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

Journal of medicinal chemistry, 2024-05, Vol.67 (11), p.8962

2024

Link zum Volltext

Verfügbarkeit prüfen

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Link zum Volltext

Verfügbarkeit prüfen

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Link zum Volltext

Verfügbarkeit prüfen

BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma

Oncogene, 2011-04, Vol.30 (17), p.2077-2085

2011

Link zum Volltext

Verfügbarkeit prüfen

Varied Clinical Ketogenic Diets Elicit Both Shared and Unique Functional and Taxonomic Responses on the Human Gut Microbiome in Refractory Epilepsy

Current developments in nutrition, 2022-06, Vol.6 (Supplement_1), p.1024-1024

2022

Link zum Volltext

Verfügbarkeit prüfen

Extended 5-Year Follow-Up Results of a Phase 1b Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Clinical cancer research, 2019-11, Vol.26 (1), p.46-53

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Englisch
(111)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Modeling initiation of Ewing sarcoma in human neural crest cells

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma

Outcome-Driven Cluster Analysis with Application to Microarray Data

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

Cobimetinib combined with vemurafenib in advanced BRAFV600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Ewing Tumors That Do Not Overexpress BMI-1 Are a Distinct Molecular Subclass with Variant Biology: A Report from the Children's Oncology Group

Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types

Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma

Varied Clinical Ketogenic Diets Elicit Both Shared and Unique Functional and Taxonomic Responses on the Human Gut Microbiome in Refractory Epilepsy

Extended 5-Year Follow-Up Results of a Phase 1b Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Suchergebnisse filtern